83 results about "Diffuse large cell lymphoma" patented technology

The invention discloses a diffuse large B-cell lymphoma segmentation system based on deep learning, and the system comprises a data collection module which is used for collecting PET and CT images of a patient; the double-branch encoder module is used for processing PET and CT images respectively; the cross-modal feature cross fusion module is used for extracting positioning clues from the CT anatomical features by taking the PET metabolic features as queries; taking CT structure characteristics as query, and screening PET high-metabolism regions; the global-attention suppression module is used for extracting global context features, performing down-sampling, remodeling input features into a low-dimensional matrix, then performing self-attention calculation, generating a sparse weight matrix for the input features based on a full connection layer, and then performing sparse attention calculation; and finally, fusing the two attention calculation results and outputting enhanced features. And the multi-scale jump connection module is used for fusing the encoder features and the decoder features and recovering spatial details.

The invention provides a method for predicting survival prognosis of a diffuse large B-cell lymphoma patient by using an N-carbohydrate chain marker, a prediction scoring system and application. The method comprises the following steps: collecting a blood sample of the diffuse large B-cell lymphoma patient; the method comprises the following steps: detecting an N-sugar chain map in a blood sample to obtain an N-sugar chain map and N-sugar chain data; the method comprises the following steps: constructing a classifier by taking detection data of each single N-sugar chain marker as an independent variable and predicting survival prognosis as a dependent variable, training a model to obtain a classification model, and predicting survival prognosis of a to-be-detected sample according to the classification model. According to the invention, the correlation between the N-sugar chain marker in the blood and the survival prognosis during diagnosis of the DLBCL patient is found for the first time, and the N-sugar chain marker can be used as an index for predicting the survival prognosis of the DLBCL patient for the first time; the N-carbohydrate chain marker prognosis prediction scoring system provided by the invention is used for predicting the survival prognosis of DLBCL patients, and a new technical means is provided for predicting the survival prognosis of the DLBCL patients.

The invention belongs to the technical field of prognosis models, and particularly relates to a diffuse large B-cell lymphoma risk prognosis model based on lactic acid metabolism related genes. The model construction comprises the following steps: S1, data acquisition and processing; s2, constructing a prognosis model; s3, verifying and evaluating the prognosis model; and S4, application of a prognosis model. GSE10846 and GSE87371 data sets are used for screening lactic acid metabolism related genes (LMRGs), a prognosis risk model is constructed and verified, and association of the prognosis risk model with clinical pathological characteristics, immune characteristics and treatment response is disclosed.

Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and / or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention relates to the technical field of biomedicine, in particular to a molecular target for treating recurrent refractory diffuse large B-cell lymphoma and application of the molecular target. According to the invention, a molecular target CSNK1E for treating recurrent refractory diffuse large B-cell lymphoma is excavated; compared with existing traditional targets of other drugs for recurrent lymphoma, the CSNK1E has a remarkable expression difference in the recurrent DLBCL, and it is indicated that the CSNK1E possibly has more remarkable advantages in treatment of the recurrent DLBCL.

The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.

The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a pharmaceutically acceptable salt thereof.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

This disclosure provides a method for treating lymphoma, the method comprising administering a bispecific CD20xCD3 antibody to a patient in need, wherein the patient is selected based on an improvement in the level of circulating tumor (ct) DNA. In some embodiments, this disclosure provides a method for identifying lymphoma patients who may respond well to a therapy comprising a bispecific CD20xCD3 antibody.

To provide a method of treating relapsed or refractory large B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, after two or more lines of systemic therapy.SOLUTION: In one aspect, provided is a method of treating relapsed or refractory large B-cell lymphoma in a patient, after two or more lines of systemic therapy, the method comprising: (a) administering a CD19-directed genetically modified autologous T-cell immunotherapy to a patient in need of treatment; and (b) monitoring the patient following the infusion for signs and symptoms of adverse reactions.SELECTED DRAWING: None

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

Provided is a method for diagnosing the prognosis and therapeutic effect for chemotherapy in patients with rheumatoid arthritis-associated lymphoproliferative disorder (RA-LPD), who have developed a lymphoproliferative disorder (LPD) during the treatment of rheumatoid arthritis (RA). This is a kit for diagnosing the prognosis and therapeutic effect for chemotherapy in rheumatic arthritis-associated lymphoproliferative disorder (RA-LPD) patients, who have developed LPD during RA treatment. The kit comprises: means for detecting an inositol 1,4,5-triphosphate receptor (ITPR) type 2 (ITPR2) gene mutation in a biological sample from a patient; and instructions for determining that the prognosis and therapeutic effect for chemotherapy are poor when an ITPR2 gene mutation is present in the biological sample from the patient. The LPD is diffuse large B-cell lymphoma (DLBCL). For the ITPR2 gene mutation, Chr12:rs26744460 is GT or GG. Use for the diagnosis of non-RA lymphoma patients is also possible.

Disclosed herein are methods for treating cancer in a subject in need thereof, comprising administering (a) an IL-2 conjugate and (b) a chimeric antigen receptor (CAR) therapy. Also disclosed herein are methods for treating diffuse large B-cell lymphoma (DLBCL) in a subject in need thereof, the methods comprising administering an IL-2 conjugate.

The invention discloses a tricyclic BCL6 degradation agent and application of the tricyclic BCL6 degradation agent. The tricyclic compound or the pharmaceutically acceptable salt and solvate thereof provided by the invention are novel in structure, and have a relatively excellent degradation effect on BCL6 protein. Therefore, the compound provided by the invention or the composition containing the compound provided by the invention has a prospect of being developed into drugs for treating diseases which are treated or relieved by degrading the BCL6 protein; cancer such as Hodgkin's lymphoma, B-cell-derived non-Hodgkin's lymphoma, T-cell-derived non-Hodgkin's lymphoma, NK / T-cell-derived non-Hodgkin's lymphoma or diffuse large B-cell lymphoma and the like can be used in the preparation of drugs.

The present invention relates to a method for predicting a response of a patient with diffuse large B-cell lymphoma (DLBCL) to anti-IL-1β therapy. This comprises detecting a mutation in the IRF2BP2 gene and / or a lack of IRF2BP2 protein expression of the patient's DLBCL cells in a sample derived from the patient. In addition, the invention relates to the use of such detection for predicting a response of the patient to IL-1β therapy and a corresponding PCR kit.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

The invention discloses a group of nucleic acid aptamers for specifically recognizing diffuse large B-cell lymphoma cells and application of the nucleic acid aptamers. The invention provides a nucleic acid aptamer capable of specifically recognizing diffuse large B-cell lymphoma cells. The nucleic acid aptamer is a single-stranded DNA molecule as shown in SEQ ID No.1. The aptamer provided by the invention can specifically detect WSU-DLCL2 cells, and is of great significance to early diagnosis and treatment of diffuse large B lymphoma.

The present invention relates to methods of treating previously untreated diffuse large B-cell lymphoma (DLBCL), which is defined as high risk according to circulating tumor DNA (ctDNA), by administering gphentumab and in combination with chemotherapy.

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and / or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer, in particular, of B cell lymphoma or B cell leukemia. The invention provides a nucleic acid encoding TCR alpha or beta chain constructs of TCR constructs capable of specifically binding to a peptide of SEQ ID NO: 1, derived from the lineage specific antigen CD22, in the context of HLA-A2 and to subsequently lyse CD22-positive cells. The invention further provides a corresponding protein and host cell. e.g., a CD8+ T cell, pharmaceutical compositions comprising the same, and therapeutic use for treatment of B cell lymphoma or B cell leukemia, such as diffuse large B-cell lymphoma (DLBCL).

The invention belongs to the technical field of biological medicines, and relates to application of cisplatin combined with triazole C in preparation of a medicine for treating diffuse large B-cell lymphoma. The research of the invention shows that cis-platinum (especially low-dose cis-platinum) can effectively inhibit DLBCL dispersion by inhibiting ATOX1 LLPS; the triazolin C can destroy a copper steady state by inhibiting lipid droplet synthesis, so that copper in cells is overloaded, and copper death is induced; animal experiments show that after the cisplatin (especially low dosage) and the triazole C are combined for use, the progress and the dissemination of the DLBCL can be remarkably inhibited, so that the lifetime is remarkably prolonged, and the purpose of treating the DLBCL is achieved.

The present invention relates to an anti-CD79B antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Furthermore, the present invention relates to a chimeric antibody and a humanized antibody comprising a CDR region of the anti-CD79B antibody, a pharmaceutical composition comprising the anti-CD79B antibody or the antigen-binding fragment thereof, and a use thereof as an anti-cancer drug. Particularly, the present invention relates to a humanized anti-CD79B antibody, and a use thereof in preparation of a drug for treating lymphoma (such as DLBCL).

The invention discloses a protein targeted degradation chimera and application thereof.The protein targeted degradation chimera is novel in chemical structure, has an excellent degradation effect on BCL6 protein, can be used for preparing BCL6 degradation agent medicine, has the prospect of being developed into medicine for treating diseases treated or relieved by degrading the BCL6 protein, and has a good application prospect. The diseases treated or relieved by degrading the BCL6 protein comprise cancers such as Hodgkin's lymphoma, B cell-derived non-Hodgkin's lymphoma, T cell-derived non-Hodgkin's lymphoma, NK / T cell-derived non-Hodgkin's lymphoma, diffuse large B cell lymphoma and the like.

The application discloses a recombinant oncolytic virus rVSV M51R The application of C in hepatitis B liver cancer belongs to the field of biological medicine. The recombinant oncolytic virus is a recombinant attenuated vesicular stomatitis virus carrying an HBV HBcAg gene and having an M-R mutation at the 51st amino acid of the M gene. The recombinant oncolytic virus is proved to have a curative effect in a tumor model, and can be used for preparing a therapeutic vaccine for HBV-positive liver cancer, HBV-positive diffuse large B-cell lymphoma and other HBV-positive tumors.

Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric / gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.

The invention provides an application of combination of a recombinant oncolytic virus and a monoclonal antibody in preparation of a medicine for treating HBV positive liver cancer. The recombinant oncolytic virus is a recombinant attenuated vesicular stomatitis virus carrying an HBV HBsAg gene and a 4-1BBL gene (wherein the 51st amino acid M in the M gene of the virus is mutated into R). The curative effect of the recombinant oncolytic virus is proved in a tumor model, and the recombinant oncolytic virus can be used for preparing therapeutic vaccines for HBV positive tumors such as HBV positive liver cancer and HBV positive diffuse large B-cell lymphoma.

The application discloses a method for screening B-cell lymphoma biomarkers and belongs to the technical field of bioinformatics. The application aims to provide a more accurate and simple method for screening B-cell lymphoma biomarkers. The application provides a method for screening B-cell lymphoma biomarkers, which utilizes scRNA-seq data of Burkitt lymphoma, diffuse large B-cell lymphoma and follicular lymphoma, splenic marginal zone lymphoma and bulk RNA-seq data of Burkitt lymphoma and diffuse large B-cell lymphoma database to screen the relationship between T / NK and myeloid cells all cell subpopulation infiltration ratio and patient survival period. The application provides a theoretical basis for screening lymphoma disease survival analysis.

The invention discloses a PET-CT medical image automatic segmentation method based on weak supervised learning, and the method comprises the steps: firstly obtaining original images of PET and CT modes, and carrying out the registration and resampling; secondly, establishing a PET-CT medical image segmentation network model based on weak supervised learning; then, establishing a point annotation data set based on the diffuse large B-cell lymphoma, and performing pseudo-label generation on the data set by using a multi-modal fusion pseudo-label generation algorithm; then, the PET image, the CT image and the pseudo tag are sent to the segmentation network model for training, and optimal parameters are stored; and finally, performing prediction segmentation on the target focus by using the optimal model. According to the method, the segmentation network model is trained by using the labels in a weak form, so that the dependence of an existing medical image segmentation algorithm on accurate annotation data is reduced.